(RS)-sibutramine
Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI) similar to certain antidepressants. Until 2010, it was widely marketed and prescribed as an adjunct in the treatment of obesity along with diet and exercise.
Key facts
- Drug.Watchedfields
- changed
- Drug.class
- Serotonin–norepinephrine reuptake inhibitor; Anoretic
- Drug.verifiedrevid
- 464390010
- Drug.IUPAC_name
- 1-(1-(4-chlorophenyl)cyclobutyl)-N,N,2,2-tetramethylpropan-1-amine
- Drug.image
- Sibutramine.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200px
- Drug.image2
- Sibutramine ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 200px
- Drug.caption
- Sibutramine (top),(S)-(−)-sibutramine (bottom)
- Drug.tradename
- Meridia, others
~14 min read
Article
14 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- Detection in body fluids
- History
- Regulatory approval, 1997–2010
- Counterfeit weight-loss products, 2008–present
- References
- External links
Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI) similar to certain antidepressants. Until 2010, it was widely marketed and prescribed as an adjunct in the treatment of obesity along with diet and exercise.
Sibutramine was originally developed in 1988 by Boots in Nottingham, UK, and manufactured and marketed by Abbott Laboratories and sold under a variety of brand names including Reductil, Meridia, Siredia, and Sibutrex. It was classified as a Schedule IV controlled substance in the United States.